<DOC>
	<DOCNO>NCT01001351</DOCNO>
	<brief_summary>PRT-201 recombinant human type-I pancreatic elastase intend local , long-lasting dilation AVG venous anastomosis outflow vein . The goal treatment improve primary patency long-term survival AVGs thereby provide patient chronic kidney disease ( CKD ) reliable durable vascular access site hemodialysis . Recent data indicate three quarter patient loss graft patency one year , indicate substantial need new therapy . This clinical trial explore safety dilatory effect topically administer PRT-201 outflow vein newly place upper extremity AVG .</brief_summary>
	<brief_title>A Study PRT-201 Administered After Arteriovenous Graft ( AVG ) Creation Patients With Chronic Kidney Disease</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>1 . Age least 18 year . 2 . Chronic kidney disease anticipate start hemodialysis within 3 month current hemodialysis dependence . 3 . Planned creation new upper extremity AVG `` jump '' graft 1 . Patients potential site upper extremity vascular access . 2 . Creation new AVG `` jump '' graft upper extremity previously treat investigational gene cell base therapy , locally investigational pharmacological agent . 3 . On physical examination mean , suspect proximal vein stenosis , occlusion , lack continuity subclavian vein , central venous stenosis central venous occlusion . 4 . History presence arterial aneurysm . 5 . Previous treatment PRT201 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Chronic Kidney Disease</keyword>
	<keyword>Arteriovenous Grafts ( AVG )</keyword>
	<keyword>Hemodialysis</keyword>
	<keyword>Vascular Access</keyword>
	<keyword>Dialysis</keyword>
	<keyword>Graft</keyword>
	<keyword>Access</keyword>
	<keyword>vonapanitase</keyword>
	<keyword>kidney</keyword>
	<keyword>renal</keyword>
</DOC>